Assessing the safety and efficacy of the FDA: the case of the Prescription Drug User Fee Acts
The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology...
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Cambridge, Mass.
National Bureau of Economic Research
2005
|
| Series: | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series
11724 |
| Subjects: | |
| Online Access: | Volltext |
| Summary: | The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about |
| Physical Description: | 41 S. graph. Darst. |
Staff View
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV023591747 | ||
| 003 | DE-604 | ||
| 005 | 20090625 | ||
| 007 | t | ||
| 008 | 051214s2005 xxud||| |||| 00||| eng d | ||
| 035 | |a (OCoLC)255206221 | ||
| 035 | |a (DE-599)BVBBV023591747 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-521 |a DE-19 | ||
| 084 | |a 15,3 |2 ssgn | ||
| 245 | 1 | 0 | |a Assessing the safety and efficacy of the FDA |b the case of the Prescription Drug User Fee Acts |c Tomas J. Philipson ... |
| 264 | 1 | |a Cambridge, Mass. |b National Bureau of Economic Research |c 2005 | |
| 300 | |a 41 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 11724 | |
| 520 | 3 | |a The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about | |
| 610 | 1 | 4 | |a United States / Food and Drug Administration |
| 650 | 4 | |a Arzneimittel | |
| 650 | 4 | |a Beschleunigung | |
| 650 | 4 | |a Finanzierung | |
| 650 | 4 | |a USA / Food and Drug Administration | |
| 650 | 4 | |a Zulassung | |
| 650 | 4 | |a Pharmazeutisches Produkt / Arzneimittelrecht / Aufsichtsbehörde / Wirtschaftspolitische Wirkungsanalyse / Wohlfahrtseffekt / USA | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Philipson, Tomas J. |e Sonstige |0 (DE-588)128733101 |4 oth | |
| 700 | 1 | |a Berndt, Ernst R. |e Sonstige |0 (DE-588)128550783 |4 oth | |
| 700 | 1 | |a Gottschalk, Adrian H. B. |e Sonstige |0 (DE-588)129709026 |4 oth | |
| 700 | 1 | |a Strobeck, Matthew W. |d 1972- |e Sonstige |0 (DE-588)130562637 |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |
| 830 | 0 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 11724 |w (DE-604)BV002801238 |9 11724 | |
| 856 | 4 | 1 | |u http://papers.nber.org/papers/w11724.pdf |z kostenfrei |3 Volltext |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016907077 | ||
Record in the Search Index
| _version_ | 1804138249472442368 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author_GND | (DE-588)128733101 (DE-588)128550783 (DE-588)129709026 (DE-588)130562637 |
| building | Verbundindex |
| bvnumber | BV023591747 |
| ctrlnum | (OCoLC)255206221 (DE-599)BVBBV023591747 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02363nam a2200457zcb4500</leader><controlfield tag="001">BV023591747</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090625 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">051214s2005 xxud||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)255206221</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023591747</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-521</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessing the safety and efficacy of the FDA</subfield><subfield code="b">the case of the Prescription Drug User Fee Acts</subfield><subfield code="c">Tomas J. Philipson ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, Mass.</subfield><subfield code="b">National Bureau of Economic Research</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">41 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">11724</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">United States / Food and Drug Administration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Arzneimittel</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Beschleunigung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Finanzierung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">USA / Food and Drug Administration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Zulassung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmazeutisches Produkt / Arzneimittelrecht / Aufsichtsbehörde / Wirtschaftspolitische Wirkungsanalyse / Wohlfahrtseffekt / USA</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Philipson, Tomas J.</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)128733101</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berndt, Ernst R.</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)128550783</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gottschalk, Adrian H. B.</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)129709026</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strobeck, Matthew W.</subfield><subfield code="d">1972-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)130562637</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">11724</subfield><subfield code="w">(DE-604)BV002801238</subfield><subfield code="9">11724</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://papers.nber.org/papers/w11724.pdf</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016907077</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV023591747 |
| illustrated | Illustrated |
| index_date | 2024-07-02T22:41:29Z |
| indexdate | 2024-07-09T21:25:11Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016907077 |
| oclc_num | 255206221 |
| open_access_boolean | 1 |
| owner | DE-521 DE-19 DE-BY-UBM |
| owner_facet | DE-521 DE-19 DE-BY-UBM |
| physical | 41 S. graph. Darst. |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | National Bureau of Economic Research |
| record_format | marc |
| series | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| series2 | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| spelling | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts Tomas J. Philipson ... Cambridge, Mass. National Bureau of Economic Research 2005 41 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 11724 The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about United States / Food and Drug Administration Arzneimittel Beschleunigung Finanzierung USA / Food and Drug Administration Zulassung Pharmazeutisches Produkt / Arzneimittelrecht / Aufsichtsbehörde / Wirtschaftspolitische Wirkungsanalyse / Wohlfahrtseffekt / USA USA Philipson, Tomas J. Sonstige (DE-588)128733101 oth Berndt, Ernst R. Sonstige (DE-588)128550783 oth Gottschalk, Adrian H. B. Sonstige (DE-588)129709026 oth Strobeck, Matthew W. 1972- Sonstige (DE-588)130562637 oth Erscheint auch als Online-Ausgabe National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 11724 (DE-604)BV002801238 11724 http://papers.nber.org/papers/w11724.pdf kostenfrei Volltext |
| spellingShingle | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series United States / Food and Drug Administration Arzneimittel Beschleunigung Finanzierung USA / Food and Drug Administration Zulassung Pharmazeutisches Produkt / Arzneimittelrecht / Aufsichtsbehörde / Wirtschaftspolitische Wirkungsanalyse / Wohlfahrtseffekt / USA |
| title | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts |
| title_auth | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts |
| title_exact_search | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts |
| title_exact_search_txtP | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts |
| title_full | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts Tomas J. Philipson ... |
| title_fullStr | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts Tomas J. Philipson ... |
| title_full_unstemmed | Assessing the safety and efficacy of the FDA the case of the Prescription Drug User Fee Acts Tomas J. Philipson ... |
| title_short | Assessing the safety and efficacy of the FDA |
| title_sort | assessing the safety and efficacy of the fda the case of the prescription drug user fee acts |
| title_sub | the case of the Prescription Drug User Fee Acts |
| topic | United States / Food and Drug Administration Arzneimittel Beschleunigung Finanzierung USA / Food and Drug Administration Zulassung Pharmazeutisches Produkt / Arzneimittelrecht / Aufsichtsbehörde / Wirtschaftspolitische Wirkungsanalyse / Wohlfahrtseffekt / USA |
| topic_facet | United States / Food and Drug Administration Arzneimittel Beschleunigung Finanzierung USA / Food and Drug Administration Zulassung Pharmazeutisches Produkt / Arzneimittelrecht / Aufsichtsbehörde / Wirtschaftspolitische Wirkungsanalyse / Wohlfahrtseffekt / USA USA |
| url | http://papers.nber.org/papers/w11724.pdf |
| volume_link | (DE-604)BV002801238 |
| work_keys_str_mv | AT philipsontomasj assessingthesafetyandefficacyofthefdathecaseoftheprescriptiondruguserfeeacts AT berndternstr assessingthesafetyandefficacyofthefdathecaseoftheprescriptiondruguserfeeacts AT gottschalkadrianhb assessingthesafetyandefficacyofthefdathecaseoftheprescriptiondruguserfeeacts AT strobeckmattheww assessingthesafetyandefficacyofthefdathecaseoftheprescriptiondruguserfeeacts |